Editorial Material
Rheumatology
Tiphaine Lenfant, Nathalie Costedoat-Chalumeau
Summary: Contemporary guidelines suggest using lower dosages of hydroxychloroquine to minimize toxicity in managing SLE, but new evidence raises concerns about increased risk of SLE flare. The benefits and risks of this controversial recommendation need to be balanced.
NATURE REVIEWS RHEUMATOLOGY
(2023)
Article
Immunology
Chiharu Hidekawa, Ryusuke Yoshimi, Yusuke Saigusa, Jun Tamura, Noriko Kojitani, Naoki Suzuki, Natsuki Sakurai, Yuji Yoshioka, Yumiko Sugiyama-Kawahara, Yosuke Kunishita, Daiga Kishimoto, Kana Higashitani, Yuichiro Sato, Takaaki Komiya, Hideto Nagai, Naoki Hamada, Ayaka Maeda, Naomi Tsuchida, Lisa Hirahara, Yutaro Soejima, Kaoru Takase-Minegishi, Yohei Kirino, Nobuyuki Yajima, Ken-ei Sada, Yoshia Miyawaki, Kunihiro Ichinose, Shigeru Ohno, Hiroshi Kajiyama, Shuzo Sato, Yasuhiro Shimojima, Michio Fujiwara, Hideaki Nakajima
Summary: Hydroxychloroquine may help extend the time until the occurrence of infection complications in patients with systemic lupus erythematosus and tends to decrease infection rates.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Rheumatology
Megan E. B. Clowse, James Oates, April Barnado, Katie Kirchoff, Ashley Blaske, Saira Z. Sheikh, Leslie J. Crofford, Amanda M. Eudy
Summary: This study aimed to investigate disparities in pregnancy outcomes between Black and White women with SLE. The study found that Black women had higher rates of adverse pregnancy outcomes in EMR-derived datasets, and SLE was frequently over-diagnosed in White women, resulting in lower rates of adverse pregnancy outcomes.
Article
Pharmacology & Pharmacy
Anick Berard, Odile Sheehy, Jin-Ping Zhao, Evelyne Vinet, Caroline Quach, Sasha Bernatsky
Summary: This study found that in a large pregnancy cohort exposed to chloroquine or hydroxychloroquine, there was no clear increased risk of prematurity, low birth weight, or major congenital malformations, although the number of exposed cases remained low.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Deepa J. Arachchillage, Mike Laffan, Charis Pericleous
Summary: Antiphospholipid syndrome (APS) is a highly prothrombotic disorder caused by thrombo-inflammatory antiphospholipid antibodies (aPL) that lead to thrombosis through various mechanisms. Obstetric complications in APS are a result of placental thrombosis, inflammation, and complement activation. While anticoagulation is the main treatment, it may not effectively prevent thrombosis recurrence in some patients, especially those with triple positive aPL.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Rheumatology
Fulvia Ceccarelli, Carmelo Pirone, Carlo Perricone, Aikaterina Selntigia, Valeria Orefice, Viviana Antonella Pacucci, Simona Truglia, Francesca Romana Spinelli, Paola Galoppi, Cristiano Alessandri, Guido Valesini, Roberto Brunelli, Giuseppina Perrone, Fabrizio Conti
Summary: The study found that pregnancy outcomes of SLE patients were not significantly different from the control group of women without autoimmune diseases, except for a higher occurrence of small for gestational age. Disease flares during pregnancy and postpartum were associated with different factors, highlighting the importance of tailored prevention and management strategies. The study emphasized the positive impact of pre-gestational counseling and a multi-disciplinary approach on pregnancy outcomes for SLE patients.
Article
Rheumatology
John A. Reynolds, Mary Gayed, Munther A. Khamashta, Francesca Leone, Veronica Toescu, Ian N. Bruce, Ian Giles, Lee-Suan Teh, Neil McHugh, Mohammed Akil, Christopher J. Edwards, Caroline Gordon
Summary: This study investigated the outcomes of children born to mothers with SLE exposed to HCQ or AZA during pregnancy. The results showed that there were no significant negative outcomes in children exposed to HCQ during pregnancy. However, the use of AZA was associated with an increased reporting of childhood infection, which requires further study.
Review
Rheumatology
Juan J. Fierro, Manuela Velasquez-Berrio, Alexandra Ospina, Svenja Henning, Karina de Leeuw, J. Angela P. Cadavid
Summary: Hydroxychloroquine (HCQ) has been shown to have positive effects in patients with refractory obstetric APS, with its mechanisms of action including binding to sialic acid on cell membranes, blocking the binding of antiphospholipid antibodies to cells, and increasing extracellular and intracellular pH levels.
RHEUMATOLOGY INTERNATIONAL
(2023)
Article
Medicine, General & Internal
Shenglong Ye, Yuanying Liu, Xueqing Zhao, Yue Ma, Yongqing Wang
Summary: This study aimed to investigate the effect of HCQ on adverse pregnancy outcomes associated with placental dysfunction in ANAs-positive patients. The results showed that the application of HCQ significantly reduced the incidence of early-onset preeclampsia and small-for-gestational-age infants in the ANAs-positive population, increased birth weight, and prolonged gestation. HCQ usage was significantly higher in the ANA-positive group compared to the weakly positive group. HCQ can be considered as a choice for improving adverse pregnancy outcomes related to placental dysfunction in this population.
FRONTIERS IN MEDICINE
(2023)
Review
Rheumatology
Yingnan Liu, Yumei Wei, Yueyi Zhang, Huixia Yang
Summary: This meta-analysis aimed to investigate the effect of hydroxychloroquine (HCQ) intervention on the incidence of preeclampsia and other maternal and fetal outcomes in pregnant women with autoimmune disorders. The findings showed that HCQ treatment significantly reduced the risk of preeclampsia and premature delivery, especially in pregnant women with lupus, by lowering the risk of gestational hypertension and preterm birth.
CLINICAL RHEUMATOLOGY
(2023)
Article
Pharmacology & Pharmacy
Maddalena Larosa, Nathalie Costedoat-Chalumeau, Gaelle Guettrot-Imbert, Veronique Le Guern, Nathalie Morel, Diogo Jesus, Luca Iaccarino, Luis Ines, Andrea Doria
Summary: This study observed 158 pregnant women with SLE and found a significant correlation between SLE-DAS and SLEPDAI. The use of SLE-DAS in the first trimester predicted maternal flares in the 2nd and 3rd trimester, demonstrating its reliability in measuring SLE activity during pregnancy.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Medicine, General & Internal
Zhengyan Hu, Rui Gao, Wanrong Huang, Huiqing Wang, Lang Qin
Summary: The additional use of HCQ may decrease the risk of high lupus activity during pregnancy and the incidence of preeclampsia for SLE patients, but it does not reduce the risk of preeclampsia for APS/aPLs patients or intrauterine growth restriction for SLE and/or APS/aPLs patients.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Physics, Fluids & Plasmas
S. Tizdast, Z. Ebadi, J. Cheraghalizadeh, M. N. Najafi, Jose S. Andrade, Hans J. Herrmann
Summary: The study explores the generalized two-dimensional Loewner exploration process with self-similar random forces and positively correlated increments, focusing on the characteristics of self-similar traces lacking conformal invariance. The model is investigated based on the input diffusivity parameter kappa, with results showing scale invariance of the generated traces.
Article
Urology & Nephrology
Chen Tang, Feng-Lei Si, Yu-Xuan Yao, Ji-Cheng Lv, Su-Fang Shi, Yu-Qing Chen, Li-Jun Liu, Hong Zhang
Summary: The study demonstrates that using HCQ for IgAN treatment during pregnancy is safe and effective in reducing proteinuria. While there were no significant differences in other pregnancy outcomes, patients treated with HCQ had a higher history of spontaneous abortion, with eGFR being a predictive factor for obstetrical complications.
Review
Pharmacology & Pharmacy
Imran H. Yusuf, Peter Charbel Issa, Seong Joon Ahn
Summary: Long-term use of hydroxychloroquine can lead to retinopathy and visual loss. The prevalence of retinal toxicity in long-term users is higher than previously estimated. Early detection through retinal imaging techniques has raised public health concerns, warranting the implementation of retinopathy screening programs.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Gastroenterology & Hepatology
Julien Kirchgesner, Rishi J. Desai, Laurent Beaugerie, Sebastian Schneeweiss, Seoyoung C. Kim
Summary: The risk of serious infections associated with vedolizumab was found to be similar to anti-TNF in patients with inflammatory bowel disease (IBD) overall, but varied according to IBD subtype, with a decreased risk for patients with ulcerative colitis (UC) and no difference for patients with Crohn's disease (CD).
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Rheumatology
Chandrasekar Gopalakrishnan, Rishi J. Desai, Jessica M. Franklin, Yinzhu Jin, Joyce Lii, Daniel H. Solomon, Jeffrey N. Katz, Yvonne C. Lee, Patricia D. Franklin, Seoyoung C. Kim
Summary: This study aimed to develop a claims-based model for predicting persistent high-dose opioid use among patients who underwent total knee replacement (TKR). The study utilized Medicare claims data and employed group-based trajectory modeling to identify different patterns of opioid use. The findings revealed that approximately 10.6% of older patients became persistent high-dose opioid users after TKR.
ARTHRITIS CARE & RESEARCH
(2022)
Article
Public, Environmental & Occupational Health
Julie M. Paik, Elisabetta Patorno, Min Zhuo, Lily G. Bessette, Cassandra York, Nileesa Gautam, Dae Hyun Kim, Seoyoung C. Kim
Summary: Validation studies compared ICD-9 and ICD-10 codes with laboratory values to identify CKD Stages 3-5 patients, finding that a two-code algorithm combined with lab results within +/- 90 days achieved the highest PPV. ICD-10 codes showed comparable accuracy to ICD-9 codes, with all ICD-10 algorithms having PPVs >80%.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
(2022)
Article
Rheumatology
Sicong Huang, Tianrun Cai, Brittany N. Weber, Zeling He, Kumar P. Dahal, Chuan Hong, Jue Hou, Thany Seyok, Andrew Cagan, Marcelo F. DiCarli, Jacob Joseph, Seoyoung C. Kim, Daniel H. Solomon, Tianxi Cai, Katherine P. Liao
Summary: This study found that elevated inflammation early in the diagnosis of rheumatoid arthritis (RA) was associated with heart failure, specifically heart failure with preserved ejection fraction (HFpEF). The association was not observed with heart failure with reduced ejection fraction (HFrEF). This finding suggests a window of opportunity for prevention of HFpEF in RA patients.
ARTHRITIS CARE & RESEARCH
(2023)
Article
Cardiac & Cardiovascular Systems
Arnaud D. Kaze, Min Zhuo, Seoyoung C. Kim, Elisabetta Patorno, Julie M. Paik
Summary: The study showed that the use of SGLT2i in patients with DKD is associated with reduced risks of MACE, kidney outcomes, HHF, and death. There is limited data on the associations between SGLT2i and safety outcomes, indicating the need for further research.
CARDIOVASCULAR DIABETOLOGY
(2022)
Article
Pharmacology & Pharmacy
Andrei Barbulescu, Johan Askling, Saedis Saevarsdottir, Seoyoung C. Kim, Thomas Frisell
Summary: This study emulated a pragmatic trial using observational data and compared it with the results of a well-known trial. The findings showed that using a prespecified protocol in clinical registry data can replicate the results of the trial, favoring infliximab over SSZ + HCQ combination therapy at 9 months.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Cardiac & Cardiovascular Systems
Min Zhuo, Seoyoung C. Kim, Elisabetta Patorno, Julie M. Paik
Summary: This study aimed to investigate whether there is a difference in the risk of hospitalization for heart failure (HHF) between the initiation of sodium zirconium cyclosilicate (SZC) and patiromer for the treatment of hyperkalemia. The results from the matched analysis showed that the use of SZC was associated with a numerically higher risk of HHF compared to patiromer, but this difference did not reach statistical significance.
JOURNAL OF CARDIAC FAILURE
(2022)
Article
Medicine, General & Internal
Rishi J. Desai, Vijay R. Varma, Tobias Gerhard, Jodi Segal, Mufaddal Mahesri, Kristyn Chin, Daniel B. Horton, Seoyoung C. Kim, Sebastian Schneeweiss, Madhav Thambisetty
Summary: This cohort study did not find any association of risk of ADRD in patients treated with tofacitinib, tocilizumab, or TNF inhibitors compared with abatacept.
Article
Rheumatology
Julie C. C. Lauffenburger, Zhigang Lu, Mufaddal Mahesri, Erin Kim, Angela Tong, Seoyoung C. C. Kim
Summary: This study used data-driven approach to classify and predict spending patterns in patients with gout. The study identified three distinct spending patterns: minimal spending, moderate spending, and high spending, and found that clinical predictors could help predict the spending groups. These findings are important for selecting appropriate interventions.
ARTHRITIS CARE & RESEARCH
(2023)
Article
Public, Environmental & Occupational Health
Hemin Lee, Jeffrey A. Sparks, Su Been Lee, Kazuki Yoshida, Joan E. Landon, Seoyoung C. Kim
Summary: This study aims to determine the accuracy of ICD-10 diagnosis codes for rheumatoid arthritis (RA) serostatus using a US claims database (Optum Clinformatics Data Mart) and compare the results to a previous study. The results showed that the PPVs for seropositive and seronegative RA in the Optum database were lower than those in MarketScan, but improved when more restricted definitions of M05 and M06 were used.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
(2023)
Article
Rheumatology
H. Lee, S. K. Chen, N. Gautam, S. M. Vine, M. He, R. J. Desai, M. E. Weinblatt, R. J. Glynn, S. C. Kim
Summary: The objective of this study was to investigate the incidence rate of skin cancer associated with methotrexate and hydroxychloroquine in older adults with rheumatoid arthritis (RA). The results showed that there was no significant difference in the risk of skin cancer between methotrexate and hydroxychloroquine users. However, methotrexate initiators had a higher risk of basal cell carcinoma (BCC) but a lower risk of squamous cell carcinoma (SCC) compared to hydroxychloroquine initiators.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
(2023)
Letter
Allergy
Lily Li, Joan E. Landon, Seoyoung C. Kim
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
(2022)
Article
Rheumatology
S. K. Tedeschi, Y. Jin, S. Vine, H. Lee, A. Pethoe-Schramm, V Yau, S. C. Kim
Summary: In these two U.S. GCA cohorts, high-dose glucocorticoids were the most common initial treatment. Over 25% of Medicare patients and 7% of MarketScan patients developed serious infections during follow-up. Older age and higher frailty score were associated with higher risk of serious infections.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Julien Kirchgesner, Rishi J. Desai, Maria C. Schneeweiss, Laurent Beaugerie, Sebastian Schneeweiss, Seoyoung C. Kim
Summary: Combination therapy with vedolizumab and thiopurines is associated with a lower risk of treatment failure compared to vedolizumab monotherapy in patients with CD, but the effect is less pronounced in UC.
Article
Urology & Nephrology
Julie M. Paik, Min Zhuo, Cassandra York, Theodore Tsacogianis, Seoyoung C. Kim, Rishi J. Desai
Summary: A study on patients with ESRD on hemodialysis in the USA found a slight reduction in overall medication burden over time, accompanied by a decrease in prescribing of several classes of harmful medications, particularly non-benzodiazepine hypnotics, benzodiazepines, and opioids.
AMERICAN JOURNAL OF NEPHROLOGY
(2022)